Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.40 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 5/20 | 0.36 |
| ▸ | DRD3 | P35462 | 4/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3537137 | 0.88 | HCAR1 (0.41) | NOTUMALDH1A1GAAMAPTKMT2A | |
| SCHEMBL3528352 | 0.79 | PDCD1 (0.45) | NOTUMALDH1A1KDM4EGAAMAPT | |
| SCHEMBL10885978 | 0.79 | GAA (0.46) | NOTUMPTPN11ALDH1A1DRD2DRD3 | |
| SCHEMBL3527797 | 0.78 | SLC9A1 (0.40) | ALDH1A1KDM4EGAAMAPTKMT2A | |
| SCHEMBL3533237 | 0.78 | MEN1 (0.45) | NOTUMALDH1A1DRD3KDM4EGAA | |
| SCHEMBL3532127 | 0.78 | MAPT (0.45) | ALDH1A1DRD3KDM4EGAAMAPT | |
| SCHEMBL3529723 | 0.77 | SHMT2 (0.43) | ALDH1A1DRD3P2RX7KDM4EGAA | |
| SCHEMBL3532077 | 0.75 | KMT2A (0.64) | ALDH1A1DRD3KDM4EGAAMAPT | |
| SCHEMBL3534430 | 0.74 | GAA (0.43) | ALDH1A1KDM4EGAAMAPTKMT2A | |
| SCHEMBL3529246 | 0.74 | ALDH1A1 (0.40) | ALDH1A1KDM4EMAPTKMT2AHCAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652057-B2 | Pyrazolones as 11b-HSD1 inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1924562-A2 | PYRAZOLONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007025880-A2 | PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | HSD11B1, HSD17B1, HSD17B7 | NOTUM 1893/4885PTPN11 1458/4885ALDH1A1 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.